Literature DB >> 8698907

Treatment of scleromyxedema with 2-chlorodeoxyadenosine.

L S Davis1, S Sanal, O P Sangueza.   

Abstract

Scleromyxedema is an unusual skin disease that is characterized by a proliferation of fibroblasts and an accumulation of mucin. Despite experience with multiple forms of therapy, no single agent has proved uniformly beneficial in this condition. We describe a patient with scleromyxedema who was treated successfully with 2-chlorodeoxyadenosine (2-CdA), a purine analog used mainly in the treatment of lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698907     DOI: 10.1016/s0190-9622(96)90650-7

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  A2B adenosine receptor activity is reduced in neutrophils from patients with systemic sclerosis.

Authors:  Laura Bazzichi; Letizia Trincavelli; Alessandra Rossi; Francesca De Feo; Antonio Lucacchini; Stefano Bombardieri; Claudia Martini
Journal:  Arthritis Res Ther       Date:  2004-12-10       Impact factor: 5.156

2.  Scleromyxedema: a rare disorder and its treatment difficulties.

Authors:  Sandra Koleta Koronowska; Agnieszka Osmola-Mańkowska; Oliwia Jakubowicz; Ryszard Zaba
Journal:  Postepy Dermatol Alergol       Date:  2013-04-12       Impact factor: 1.837

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.